Patents by Inventor Matteo D'este
Matteo D'este has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230113554Abstract: A method of producing a pharmaceutical gel emulsion, wherein the emulsion is an oil-in-water gel emulsion, comprising the steps of forming an oil-in-water emulsion comprising at least one pharmaceutically acceptable oil, at least one aqueous phase, at least one osmotic agent, at least one emulsifying agent, mixing a gelling polysaccharide with the oil-in-water emulsion and allowing the resulting mixture to form the pharmaceutical gel emulsion, optionally mixing an bioactive agent into the pharmaceutical gel emulsion.Type: ApplicationFiled: December 10, 2020Publication date: April 13, 2023Applicant: AO TECHNOLOGY AGInventor: Matteo D'ESTE
-
Patent number: 11198741Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.Type: GrantFiled: August 26, 2019Date of Patent: December 14, 2021Assignee: FIDIA FARMACEUTICI S.p.A.Inventors: Matteo D'Este, Giovanni Gennari
-
Publication number: 20200010573Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.Type: ApplicationFiled: August 26, 2019Publication date: January 9, 2020Applicant: Fidia Farmaceutici S.p.A.Inventors: Matteo D'ESTE, Giovanni GENNARI
-
Patent number: 10435483Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.Type: GrantFiled: October 27, 2016Date of Patent: October 8, 2019Assignee: FIDIA FARMACEUTICI S.P.A.Inventors: Matteo D'Este, Giovanni Gennari
-
Publication number: 20170107303Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.Type: ApplicationFiled: October 27, 2016Publication date: April 20, 2017Applicant: Fidia Farmaceutici S.p.A.Inventors: Matteo D'ESTE, Giovanni GENNARI
-
Patent number: 9504708Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.Type: GrantFiled: May 14, 2010Date of Patent: November 29, 2016Assignee: FIDIA FARMACEUTICI S.p.A.Inventors: Matteo D'Este, Giovanni Gennari
-
Publication number: 20160220685Abstract: The present invention provides for a method for preparing a thermosensitive hyaluronic acid conjugate comprising the steps of contacting, in any order, a. a predefined amount of hyaluronic acid, b. a predefined amount of one or more thermosensitive polymers having at least one terminal amine moiety and c. a predefined amount of a 1,3,5-triazine (or s-triazine) compound; as well as the conjugates obtainable thereby.Type: ApplicationFiled: October 2, 2013Publication date: August 4, 2016Applicant: AO TECHNOLOGY AGInventors: Matteo D'ESTE, David Olivier EGLIN, Robert Geoffrey RICHARDS, Mauro ALINI
-
Patent number: 9034624Abstract: The present invention relates to a process for the synthesis of conjugates of glycosaminoglycanes (GAG) with biologically active molecules of varying nature, comprising small molecules and macro-molecules. In particular, the present invention relates to the conjugation of hyaluronic acid (HA) and its derivatives with polypeptides and proteins with a biological action, such as, for example, interferons, erythropoietins, growth factors, insulin, cytokines, antibodies and hormones. An object of the present invention also relates to isolatable intermediates obtained by the partial or total reaction of GAG with protected amino aldehydes in the conjugation process mentioned above.Type: GrantFiled: June 4, 2010Date of Patent: May 19, 2015Assignee: FIDIA FARMACEUTICI S.P.A.Inventors: Matteo D'Este, Davide Renier, Gianfranco Pasut, Antonio Rosato
-
Patent number: 8969320Abstract: Disclosed are hyaluronic acid derivatives functionalized with S-nitrosothiol groups of the general formula: wherein HA indicates hyaluronic acid and G indicates a suitable spacer.Type: GrantFiled: February 1, 2013Date of Patent: March 3, 2015Assignee: Fidia Farmaceutici S.p.A.Inventors: Davide Renier, Matteo D'Este
-
Patent number: 8846640Abstract: Biomaterials obtainable by mixing the autocrosslinked derivative of hyaluronic acid (ACP) with the derivative (HBC) of hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE) in the weight ratio of between 10:90 and 90:10 as novel fillers.Type: GrantFiled: August 25, 2010Date of Patent: September 30, 2014Assignee: Fidia Farmaceutici S.p.A.Inventors: Matteo D'este, Davide Renier
-
Publication number: 20120190644Abstract: Biomaterials obtainable by mixing the autocrosslinked derivative of hyaluronic acid (ACP) with the derivative (HBC) of hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE) in the weight ratio of between 10:90 and 90:10 as novel fillers.Type: ApplicationFiled: August 25, 2010Publication date: July 26, 2012Applicant: FIDIA FARMACEUTICI S.p.A.Inventors: Matteo D'este, Davide Renier
-
Publication number: 20120121572Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature.Type: ApplicationFiled: May 14, 2010Publication date: May 17, 2012Applicant: FIDIA FARMACEUTICI S.P.A.Inventors: Matteo D'Este, Giovanni Gennari
-
Publication number: 20120114602Abstract: The present invention relates to a process for the synthesis of conjugates of glycosaminoglycanes (GAG) with biologically active molecules of varying nature, comprising small molecules and macro-molecules. In particular, the present invention relates to the conjugation of hyaluronic acid (HA) and its derivatives with polypeptides and proteins with a biological action, such as, for example, interferons, erythropoietins, growth factors, insulin, cytokines, antibodies and hormones. An object of the present invention also relates to isolatable intermediates obtained by the partial or total reaction of GAG with protected amino aldehydes in the conjugation process mentioned above.Type: ApplicationFiled: June 4, 2010Publication date: May 10, 2012Applicant: FIDIA FARMACEUTICI S.p.A.Inventors: Matteo D'Este, Davide Renier, Gianfranco Pasut, Antonio Rosato
-
Publication number: 20100197631Abstract: Disclosed are hyaluronic acid derivatives functionalised with S-nitrosothiol groups of the general formula: wherein HA indicates hyaluronic acid and G indicates a suitable spacer.Type: ApplicationFiled: June 25, 2008Publication date: August 5, 2010Applicant: FIDIA FARMACEUTICI S.p.A.Inventors: Davide Renier, Matteo D'este